Trial reportThe journal of headache and pain2019
Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Trial report in The journal of headache and pain, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Monoclonal Antibody Duration of REsponse in MIgraine After Treatment Interruption: A Prospective National Study
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Pooled it
- Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis.Journal of neurology · 2021Pooled it
- Pooled it
- Timing of Effect Onset After Restarting Anti CGRP-(Receptor)-Monoclonal Antibodies Following a Mandatory Cessation After One year of Use-A Single Center Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Neurology and therapy · 2023Article
- The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics.The journal of headache and pain · 2023Article
- Article
- Unmet Needs in Preventive Treatment of Migraine.Neurology and therapy · 2023Article
- [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis].Der Nervenarzt · 2023Review
- Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review.Life (Basel, Switzerland) · 2023Review
- The sense of stopping migraine prophylaxis.The journal of headache and pain · 2023Review
- Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials.Frontiers in neurology · 2023Review
- Galcanezumab modulates Capsaicin-induced C-fiber reactivity.Cephalalgia : an international journal of headache · 2022Article
- Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.Brain and behavior · 2022Article
- CGRP Targeting Therapy for Chronic Migraine-Evidence from Clinical Trials and Real-world Studies.Current pain and headache reports · 2022Review
- Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study.Cephalalgia : an international journal of headache · 2022Article
- Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes.Therapeutics and clinical risk management · 2022Review
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.The journal of headache and pain · 2021Observational
- Preventive treatment with CGRP monoclonal antibodies restores brain stem habituation deficits and excitability to painful stimuli in migraine: results from a prospective case-control study.The journal of headache and pain · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMonoclonal antibodies (mAbs) targeting the CGRP pathway are safe and efficacious therapies for the prevention of migraine. In this study we assessed the effects of discontinuation of preventive erenumab and galcanezumab treatment in patients with chronic migraine.
methodsThis retrospective pooled analysis included completers of the open-label extension study phase for the preventive treatment of chronic migraine with galcanezumab (NCT02614261; 9 months) and erenumab (NCT02174861; 12 months) in a single headache center. We compare migraine data until week 12 after open-label treatment completion, when patients did not have any pharmacological preventive medication, to study baseline values of the double-blind trial period, and to the last 4 weeks of the open-label extension. The assessment included changes in monthly migraine days, headache hours, days with severe headache and acute headache medication use.
resultsData from 16 patients after galcanezumab (n = 9) and erenumab (n = 7) open-label treatment completion were analyzed. The mean number of monthly migraine days was 18.38 ± 3.74 at baseline, and 12.19 ± 4.53 in the last 4 weeks of the open-label extension (p < 0.001). Monthly migraine days remained significantly reduced compared to baseline during the entire 12-week observation period after open-label termination (p = 0.002), with a reduction of 5.38 ± 4.92 in weeks 1-4 (p = 0.001), 4.75 ± 4.15 in weeks 5-8 (p = 0.001), and 3.93 ± 5.45 in weeks 9-12 (p = 0.014). There was no significant difference in monthly migraine days between the 12 weeks after open-label termination and the last 4 weeks of the open-label phase (p = 0.228). All other analyses revealed numerical improvement through week 12 in comparison to baseline.
conclusionsIn this small, self-selected cohort, the results indicate a therapeutic effect of monoclonal antibodies targeting the CRGP pathway in chronic migraine prevention after treatment termination up to 12 weeks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.